Test Background Apixaban is a direct oral anticoagulant (DOAC) which exerts its anticoagulant effect through its ability to directly inhibit Coagulation Factor X. Plasma Apixaban levels are measured in mass concentration by chromogenic anti-Xa assay using drug-specific calibrators.
Recommended as an option for (NICE Guidelines 2016 – KTT16)
• Prevention of VTE after elective hip or knee replacement • Treatment and secondary prevention of DVT and/or PE • Prevention of stroke and systemic embolism in people with non-valvular AF
DOAC monitoring is not generally required; however measurement may be useful where clearance is compromised or where patients are actively bleeding.
BCSH Guidelines (2014) Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: